For most people there are few side effects
Several major studies reported average body-weight reductions approaching 25-30%, placing Retatrutide among the most promising metabolic peptides currently under investigation
Among the 18% of adults who report having ever used GLP-1 drugs, the vast majority (84%) say they have been diagnosed with at least one of the predominant conditions these drugs are prescribed to treat, including obesity or being overweight in the past five years (77%), or ever being diagnosed with diabetes (49%) or heart disease (21%)
The financial picture between these two compounds is vastly different right now, and that difference will persist even after retatrutide gains approval
Grocery Spending Since starting GLP-1, the average respondent's personal grocery bill decreased from $351 to $282 monthly, a 20% reduction
So the upward line from semaglutide to tirzepatide to retatrutide is best read as a hypothesis strongly supported by early evidence, not as a law guaranteeing that triple agonism will end up strictly superior once the full safety and durability picture is in
